

Draft for Consultation

# Asthma: diagnosis, monitoring and chronic asthma management (update)

*NICE guideline <number>*

*June 2024*

**Methodology**

*Draft for Consultation*  
*Developed by NICE*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2024. All rights reserved. Subject to [Notice of rights](#).

# Contents

<b>1</b>	<b>Development of the guideline</b> .....	<b>5</b>
1.1	Remit.....	5
1.2	What this guideline covers.....	5
1.3	What this guideline does not cover .....	5
<b>2</b>	<b>Methods</b> .....	<b>6</b>
2.1	Developing the review questions and outcomes .....	6
2.1.1	Stratification .....	28
2.2	Searching for evidence.....	30
2.2.1	Clinical and health economics literature searches .....	30
2.3	Reviewing evidence .....	31
2.3.1	Types of studies and inclusion and exclusion criteria .....	32
2.4	Methods of combining evidence .....	32
2.4.1	Data synthesis for intervention reviews .....	32
2.4.2	Data synthesis for diagnostic reviews .....	34
2.5	Appraising the quality of evidence by outcomes .....	35
2.5.1	Intervention reviews .....	35
2.5.2	Diagnostic reviews .....	43
2.6	Assessing clinical importance.....	45
2.6.1	Literature review .....	46
2.6.2	Undertaking new health economic analysis.....	48
2.6.3	Cost-effectiveness criteria .....	49
2.6.4	In the absence of health economic evidence.....	49
2.7	Developing recommendations .....	49
2.7.1	Research recommendations .....	51
2.7.2	Validation process.....	51
2.7.3	Updating the guideline .....	51
2.8	General terms [methodological terms].....	51
2.9	Acronyms and abbreviations .....	63
2.10	Glossary.....	64
<b>3</b>	<b>References</b> .....	<b>67</b>

# 1 Development of the guideline

## 1.1 Remit

NICE received the remit for this guideline from NHS England.

The remit for this guideline was to update the following clinical guidelines: NICE Guideline: Asthma: diagnosis, monitoring and chronic asthma management (NG80) and the BTS/SIGN Guideline: British guideline on the management of asthma (SIGN158).

## 1.2 What this guideline covers

The following sections of the guidelines will be updated:

- Initial clinical assessment and diagnosis
- Monitoring, ongoing assessment & risk stratification
- Pharmacological management of chronic asthma

The recommendations from the following sections from both guidelines will be editorially refreshed and aligned:

- Supported self-management
- Inhaler devices
- Asthma in adolescents
- Occupational asthma

## 1.3 What this guideline does not cover

The recommendations from the following sections from the SIGN/BTS asthma guideline and NG121 section 1.4 'Asthma' are editorially refreshed and aligned:

- Asthma in pregnancy

The following SIGN/BTS guideline sections are not included in the update:

- Non-pharmacological management
- Management of acute asthma
- Management of difficult asthma
- Organisation and delivery of care

## 2 Methods

This guideline was developed using the methods described in the NICE guidelines manual (National Institute for Health and Care Excellence, 2014), updated 2020. Declarations of interest were recorded according to the NICE conflicts of interest policy.

Sections 2.1 to 2.3 describe the process used to identify and review evidence. Sections 2.1.1 and 0 describe the process used to identify and review the health economic evidence.

### 2.1 Developing the review questions and outcomes

The review questions developed for this guideline were based on the key areas and draft review questions identified in the guideline scope. They were drafted by the technical team, refined and validated by the committee and signed off by NICE. A total of 24 review questions were developed in this guideline and outlined in Table 1. Diagnostic questions, which included diagnostic accuracy and test-and-treat methods were combined, resulting in 18 questions.

The review questions were based on the following frameworks:

- population, intervention, comparator and outcome (PICO) for reviews of interventions (including test and treat)
- population, index tests, reference standard and target condition for reviews of diagnostic test accuracy

This use of a framework informed a more detailed protocol that guided the literature searching process, critical appraisal and synthesis of evidence, and facilitated the development of recommendations by the guideline committee. Full literature searches, critical appraisals and evidence reviews were completed for all the specified review questions.

**Table 1: Review questions**

Evidence report	Type of review	Review questions	Outcomes
A Accuracy and clinical and cost-effectiveness of spirometry for diagnosis of asthma	Diagnostic: Test and treat and diagnostic accuracy	In people under investigation for asthma, what is the diagnostic test accuracy and clinical and cost-effectiveness of spirometry?	Clinical effectiveness (test and treat) outcomes: <ul style="list-style-type: none"><li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li><li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li><li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li></ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events               <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> </ul> </li> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>• Sensitivity (thresholds: upper 90, lower 10)</li> <li>• Specificity (thresholds: upper 80, lower 50)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
<p>B Accuracy and clinical and cost-effectiveness of bronchodilator response in the diagnosis of asthma</p>	<p>Diagnostic: Test and treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and clinical and cost-effectiveness of bronchodilator response (using PEF or FEV1)?</p>	<ul style="list-style-type: none"> <li>• Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul> <ul style="list-style-type: none"> <li>• Clinical effectiveness (test and treat)</li> <li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at ≥6 months, latest timepoint if more than one)</li> <li>• Mortality (dichotomous outcome at ≥6 months)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at ≥3 months)</li> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at ≥3 months)</li> <li>• Hospital admissions (dichotomous outcome at ≥6 months)</li> <li>• Reliever/rescue medication use (continuous outcome at ≥3 months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at ≥3 months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events: <ul style="list-style-type: none"> <li>○ linear growth (continuous outcome at ≥1 year)</li> <li>○ pneumonia frequency (dichotomous outcome at ≥3 months)</li> </ul> </li> </ul>



Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>○ adrenal insufficiency (as defined by study, including short synacthen test and morning cortisol, dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> <li>● Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>● Sensitivity (thresholds: upper 90%, lower 10%)</li> <li>● Specificity (thresholds: upper 80%, lower 50%)</li> <li>● Positive predictive value (PPV) and negative predictive value (NPV)</li> </ul>
<p>C Accuracy and clinical and cost-effectiveness of peak expiratory flow in the diagnosis of asthma</p>	<p>Diagnostic: Test and treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and clinical and cost-effectiveness of peak expiratory flow (PEF) variability?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>● Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li> <li>● Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>● Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>● Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>● Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>● Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> </ul> <p>Adverse events</p> <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> </ul> <ul style="list-style-type: none"> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>• Sensitivity (Threshold: upper 90%, lower 10%)</li> <li>• Specificity (Threshold: upper 80%, lower 50%)</li> <li>• Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
<p>D Accuracy and clinical and cost-effectiveness of skin prick test in children for</p>	<p>Diagnostic: Test and treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of skin prick tests in children?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
diagnosis of asthma			<ul style="list-style-type: none"> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> </ul> <p>Adverse events</p> <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> </ul> <ul style="list-style-type: none"> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Sensitivity (thresholds: upper 90, lower 10)</li> <li>• Specificity (thresholds: upper 80, lower 50)</li> <li>• Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
<p>E Accuracy and clinical and cost-effectiveness of serum IgE measures in diagnosing asthma in children</p>	<p>Diagnostic: Test and treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of total and specific serum IgE measures in children?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> </ul> <p>Adverse events</p> <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>○ Pneumonia frequency (dichotomous outcome at ≥3 months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at ≥3 months)</li> <li>○ Bone mineral density (continuous outcome at ≥6 months)</li> <li>● Inflammatory markers; exhaled nitric oxide (continuous outcome at ≥8 weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>● Sensitivity (thresholds: upper 90, lower 10)</li> <li>● Specificity (thresholds: upper 80, lower 50)</li> <li>● Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
<p>F Accuracy and clinical and cost-effectiveness of FeNO in the diagnosis of asthma</p>	<p>Diagnostic: Test and treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and clinical and cost effectiveness of fractional exhaled nitric oxide (FeNO) measures?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>● Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at ≥6 months)</li> <li>● Mortality (dichotomous outcome at ≥6 months)</li> <li>● Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at ≥3 months)</li> <li>● Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at ≥3 months)</li> <li>● Hospital admissions (dichotomous outcome at ≥6 months)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events               <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year)</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> </ul> </li> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>• Sensitivity (thresholds: upper 90, lower 10)</li> <li>• Specificity (thresholds: upper 80, lower 50)</li> </ul> <p>Negative predictive value (NPV), Positive predictive value (PPV)</p>
G Accuracy and clinical and cost-effectiveness of	Diagnostic: Test and treat and diagnostic accuracy	In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of eosinophil blood count measures?	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
eosinophil blood count measures in the diagnosis of asthma			<p>use (dichotomous outcome at <math>\geq 6</math> months)</p> <ul style="list-style-type: none"> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> </ul> <p>Adverse events</p> <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>• Sensitivity (thresholds: upper 90, lower 10)</li> <li>• Specificity (thresholds: upper 80, lower 50)</li> <li>• Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
<p>H Accuracy and clinical and cost-effectiveness of histamine and methacholine in the diagnosis of asthma</p>	<p>Diagnostic: Test and treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and clinical and cost-effectiveness of bronchial challenge testing (direct) with histamine and methacholine?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events</li> </ul>



Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> <li>○ Acute symptoms (dichotomous outcome reported immediately post-test (<math>\leq 10</math> mins))</li> <li>● Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>● Sensitivity (thresholds: upper 90, lower 10)</li> <li>● Specificity (thresholds: upper 80, lower 50)</li> <li>● Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
<p>I Accuracy and clinical and cost-effectiveness of bronchial challenge testing (indirect) with mannitol in diagnosing asthma</p>	<p>Diagnostic: Test and treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and clinical and cost-effectiveness of bronchial challenge testing (indirect) with mannitol?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>● Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li> <li>● Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>● Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>● Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<p>respiratory) (continuous outcome at <math>\geq 3</math> months)</p> <ul style="list-style-type: none"> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> <li>○ Acute symptoms (any symptom e.g. flushing, coughing, may be referred to as tolerability/acceptability – time frame immediately post-test (10 mins)</li> </ul> </li> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>• Sensitivity (thresholds: upper 90, lower 10)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Specificity (thresholds: upper 80, lower 50)</li> <li>• Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
<p>J Accuracy and clinical and cost-effectiveness of bronchial challenge testing in response to exercise in diagnosis of asthma</p>	<p>Diagnosis: test-and-treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic accuracy and clinical and cost-effectiveness of bronchoconstriction in response to an exercise challenge?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events               <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year)</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> </ul> </li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> <li>○ Acute symptoms (dichotomous outcome reported immediately post-test (&lt;10 mins))</li> <li>● Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>● Sensitivity (thresholds: upper 90, lower 10)</li> <li>● Specificity (thresholds: upper 80, lower 50)</li> <li>● Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
<p>K Accuracy and clinical and cost-effectiveness of combination tests for diagnosis in people with suspected asthma</p>	<p>Diagnosis: test-and-treat and diagnostic accuracy</p>	<p>In people under investigation for asthma, what is the diagnostic test accuracy and clinical and cost-effectiveness of a combination of tests?</p>	<p>Clinical effectiveness (test and treat) outcomes:</p> <ul style="list-style-type: none"> <li>● Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at <math>\geq 6</math> months))</li> <li>● Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>● Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>● Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Hospital admissions (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events               <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> <li>○ Acute symptoms (any symptom e.g. flushing, coughing, may be referred to as tolerability/acceptability – time frame immediately post-test (10 mins)</li> </ul> </li> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul> <p>Diagnostic accuracy outcomes: Asthma diagnosis</p> <ul style="list-style-type: none"> <li>• Sensitivity (thresholds: upper 90, lower 10)</li> <li>• Specificity (thresholds: upper 80, lower 50)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>Negative predictive value (NPV), Positive predictive value (PPV)</li> </ul>
L Symptoms scores/diaries or validated questionnaires measuring symptom control to monitor asthma	Intervention	In people with asthma, what is the clinical and cost-effectiveness of using symptom scores/diaries or validated questionnaires measuring symptom control (e.g. ACT, ACQ, CACT, RCP 3 questions) and/or health related quality of life (e.g. AQLQ, PAQLQ) to monitor asthma?	<ul style="list-style-type: none"> <li>Mortality</li> <li>Unscheduled healthcare utilisation (ED/A&amp;E visit; hospital admissions; GP out of hours or walk-in centre)</li> <li>Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use-dichotomous outcome at <math>\geq 6</math> months, latest time point if more than one)</li> <li>Asthma control assessed by a validated questionnaires (ACQ, ACT; CACT; PACQ; RCP-3; continuous outcome at <math>\geq 3</math> months)</li> <li>Quality of life (QoL) (validated scale, including asthma specific questionnaires AQLQ; health related, pAQLQ; St George's respiratory questionnaire; continuous outcome at <math>\geq 3</math> months)</li> <li>Lung function (FEV1, PEF)</li> <li>Symptoms (annual symptom free days)</li> <li>Dose of regular asthma therapy / preventer medication (ICS dose)</li> <li>Reliever/ Rescue medication use (SABA use – continuous outcome at <math>\geq 3</math> months)</li> <li>Time off school or work</li> </ul>
M Pulmonary function: spirometry or peak expiratory flow to monitor asthma	Intervention	In people with asthma, what is the clinical and cost-effectiveness of using measures of pulmonary function assessing asthma control (for example, spirometry and peak expiratory flow) to monitor asthma?	<ul style="list-style-type: none"> <li>Mortality</li> <li>Unscheduled healthcare utilisation (ED/A&amp;E visit; hospital admissions; GP out of hours or walk-in centre)</li> <li>Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use- dichotomous outcome at <math>\geq 6</math> months, latest time point if more than one)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Asthma control (assessed by validated questionnaires (ACT; CACT; ACQ; PACQ; RCP-3; continuous outcome at ≥3 months)</li> <li>• Quality of life (QoL assessed via any validated scale including asthma specific questionnaires: AQLQ; pAQLQ; St George's respiratory questionnaire; continuous outcome at ≥3 months)</li> <li>• Lung function (FEV1, PEF)</li> <li>• Symptoms (annual symptom free days)</li> <li>• Dose of regular asthma therapy / preventer medication (ICS dose)</li> <li>• Reliever/Rescue medication (SABA use; continuous at ≥3months)</li> <li>• Time off school or work</li> </ul>
<p>N FeNO measures to monitor asthma</p>	<p>Intervention</p>	<p>In people with asthma, what is the clinical and cost-effectiveness of using fractional exhaled nitric oxide (FeNO) measures for monitoring asthma control?</p>	<ul style="list-style-type: none"> <li>• Mortality (both asthma-related and all-cause)</li> <li>• Unscheduled healthcare utilisation (ED/A&amp;E visit; hospital admissions; GP out of hours or walk-in centre)</li> <li>• Severe asthma exacerbations (defined as need for course of oral steroids; dichotomous outcome at ≥6 months)</li> <li>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3; continuous outcome at ≥3 months)</li> <li>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire; continuous outcome at ≥3 months)</li> <li>• Lung function (FEV1, PEF)</li> <li>• Symptoms (annual symptom free days)</li> <li>• Dose of regular asthma therapy / preventer medication (ICS dose)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>• Rescue medication (SABA use) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Time off school or work</li> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul>
O Risk stratified care for people with asthma	Intervention	What is the clinical and cost-effectiveness of risk stratification in delivering asthma care in adults, children and young people?	<ul style="list-style-type: none"> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months; time-to-event)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Asthma control (assessed by validated questionnaire: ACQ, ACT, St George's respiratory; continuous outcome at <math>\geq 3</math> months)</li> <li>• Severe asthma exacerbations (event-rate and dichotomous) usually defined by the requirement of a course of oral steroids)</li> <li>• Moderate asthma exacerbations (event rate and dichotomous)- as defined by the study</li> <li>• Steroid use</li> <li>• Unscheduled healthcare utilisation (hospital admissions, emergency room/A&amp;E attendance and out of hours doctor/clinic visit)</li> </ul>
P Pharmacological management of asthma in people who are treatment-naïve or receiving SABA-only	Intervention	What is the most clinically and cost-effective drug class or combination of drug classes (short-acting beta agonist [SABA] prn, SABA prn plus regular inhaled corticosteroid [ICS], or ICS plus SABA / long-acting beta-agonist [LABA] combination inhaler prn) for the management of asthma in people who are treatment-naïve or receiving SABA alone?	<ul style="list-style-type: none"> <li>• Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at 3-5 and <math>\geq 6</math> months)</li> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ;</li> </ul>



Evidence report	Type of review	Review questions	Outcomes
			<p>health-related) (continuous outcome at <math>\geq 3</math> months)</p> <ul style="list-style-type: none"> <li>• Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at 3-5 and <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months) (including lower respiratory and general, in that order, respiratory tract infections, but not including upper respiratory tract infections)</li> <li>○ Adrenal insufficiency as defined by study, including short synacthen test and morning cortisol (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ Bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> </ul> </li> <li>• Inflammatory markers; exhaled nitric oxide (FeNO) (continuous outcome at <math>\geq 8</math> weeks)</li> </ul>
Q Drug combinations and	Drug combinations and	What is the most clinically and cost-effective sequence in which to introduce additional drugs or	<ul style="list-style-type: none"> <li>• Severe asthma exacerbations (defined as asthma exacerbations</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
sequencing for asthma management.	sequencing for asthma management	combination of drugs for the management of asthma when initial management fails to provide adequate control?	<p>requiring oral corticosteroid use (dichotomous outcome at 3-5 months and <math>\geq 6</math> months)</p> <ul style="list-style-type: none"> <li>• Severe exacerbation rate (event rate per person year/rate per patient year)</li> <li>• Mortality (dichotomous outcome at <math>\geq 6</math> months)</li> <li>• Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Asthma control assessed by a validated questionnaire (ACQ/p ACQ, ACT, St George's respiratory) (continuous outcome at <math>\geq 3</math> months)</li> <li>• Hospital admissions (dichotomous outcome at 3-5 months and <math>\geq 6</math> months)</li> <li>• Reliever/rescue medication use (continuous outcome at <math>\geq 3</math> months)</li> <li>• Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF) (continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</li> <li>• Adverse events (to be extracted as general adverse events minus specific adverse events reported below): <ul style="list-style-type: none"> <li>○ Linear growth (continuous outcome at <math>\geq 1</math> year),</li> <li>○ Pneumonia frequency dichotomous outcome at <math>\geq 3</math> months, including lower respiratory and general, in that order, respiratory tract infections, but not including</li> </ul> </li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> <li>upper respiratory tract infections)</li> <li>○ Adrenal insufficiency (as defined by study, including short synacthen test and morning cortisol, dichotomous outcome at ≥3 months)</li> <li>○ Bone mineral density (continuous outcome at ≥6 months)</li> <li>● Inflammatory markers; exhaled nitric oxide (continuous outcome at ≥8 weeks)</li> </ul>
<p>R Smart preventer/maintenance inhalers for the management of asthma</p>	<p>Intervention</p>	<p>What is the clinical and cost-effectiveness of smart preventer/maintenance inhalers for the management of asthma?</p>	<ul style="list-style-type: none"> <li>● Severe asthma exacerbations (defined as asthma exacerbations requiring oral corticosteroid use (dichotomous outcome at ≥6 months, latest timepoint if more than one)</li> <li>● Mortality (dichotomous outcome at ≥6 months)</li> <li>● Quality of life (QOL; validated scale, including asthma specific questionnaires AQLQ; health-related) (continuous outcome at ≥3 months)</li> <li>● Asthma control assessed by a validated questionnaire (ACQ, ACT, St George's respiratory) (continuous outcome at ≥3 months)</li> <li>● Hospital admissions (dichotomous outcome at ≥6 months)</li> <li>● Reliever/rescue medication use (continuous outcome at ≥3 months)</li> <li>● Adherence - prioritised as 1) % of puffs taken as prescribed (number of and timing of) could be reported as continuous or dichotomous and 2) Count of number times inhaler used</li> <li>● Lung function (change in FEV1 or morning PEF - average over at least 7 days for morning PEF)</li> </ul>

Evidence report	Type of review	Review questions	Outcomes
			<p>(continuous outcome at <math>\geq 3</math> months). Note: Extract FEV1 %pred over litres if both are reported. If only litres is reported, extract and analyse separately (do not extract both). For children, only use FEV1 %pred.</p> <ul style="list-style-type: none"> <li>• Adverse events: <ul style="list-style-type: none"> <li>○ linear growth (continuous outcome at <math>\geq 1</math> year)</li> <li>○ pneumonia frequency (dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ adrenal insufficiency (as defined by study, including short synacthen test and morning cortisol, dichotomous outcome at <math>\geq 3</math> months)</li> <li>○ bone mineral density (continuous outcome at <math>\geq 6</math> months)</li> </ul> </li> <li>• Inflammatory markers; exhaled nitric oxide (continuous outcome at <math>\geq 8</math> weeks)</li> </ul>

1

## 2 2.1.1 Stratification

3 Stratification is applied where the committee are confident the intervention will work  
4 differently in the groups and separate recommendations are required, therefore they  
5 should be reviewed separately. In this guideline all analyses were stratified for age (5  
6 to 16 years old and 17 years or over), which meant that different studies with  
7 predominant age-groups in different age strata were not combined and analysed  
8 together. Where studies reported a mix of populations across strata, a threshold of  
9 [80%] was agreed with the committee as a cut off for what would be acceptable to  
10 constitute a predominant group.

11 Population stratification:

12 In reviews: 1.1, 1.2, 1.3, 1.6, 1.7, 1.8, 1.9, 1.10, 1.11, 2.2, 2.3

13 Ages stratified into the following 2 groups:

- 14 • Children and young people (5-16 years old)
- 15 • Adults ( $\geq 17$  years old)

16 In reviews: 1.4, 1.5, 2.1

17 Age stratified into the following 3 groups:

- 18 • Children (<5 years old)

- 1 • Children and young people (5-16 years)  
2 • Adults (>17 years old)  
3  
4 In review: 1.4, 1.5, 1.6,  
5 • People on steroid inhalers (washout period minimum of 4 weeks for inclusion)  
6  
7 In review: 1.6, 1.7, 1.8, 1.10  
8 Stratified by smoking status:  
9 • Smokers  
10 • Non-smokers  
11 • Mixed populations  
12  
13 In review 2.3:  
14 • Population of current smokers greater than 20%  
15 • Population of current smokers less than 20%  
16  
17 In review 2.4:  
18 • Infants <5 years old, children and young people 5-16 years old  
19 • Adults >17 years  
20  
21 In review 3.1:  
22 • Infants and children <5 years old  
23 • Children 5-11 years old  
24 • Young people and adults  $\geq 12$  years old  
25  
26 In review 3.2:  
27 • Infants and children under 5 years old  
28 • Children 5-11 years old  
29 • Adults and adolescents ( $\geq 12$  years old)  
30  
31 Intervention stratification:  
32 Maintenance therapies:  
33 Step 3.2A: people ( $\geq 12$  years old)  
34 All treatment options for this population grouped depending upon the as-needed (prn)  
35 medication:  
36 • ICS/LABA  
37 • SABA  
38 • Regular low dose ICS  
39 • Regular low dose ICS inhaler  
40  
41 Step 3.2B: people ( $\geq 12$  years old)  
42 • ICS/Formoterol (MART)  
43 • SABA  
44 • Regular moderate/high dose ICS/LABA (formoterol, salmeterol, indacaterol or vilanterol)  
45 combination inhaler or concurrent inhalers  
46 • Regular low/moderate dose ICS/LABA combination inhaler plus montelukast  
47 • Regular low/moderate dose ICS/LABA combination inhaler plus LAMA

- 1 • Regular moderate/high dose ICS inhaler
- 2 • Regular low/moderate dose ICS inhaler plus montelukast
- 3 • Regular low/moderate dose ICS inhaler plus LAMA
- 4 • ICS/SABA combination inhaler prn
- 5
- 6 Children 5-11 years
- 7 • Regular paediatric moderate dose ICS/LABA with SABA prn
- 8 • Regular paediatric moderate ICS and montelukast with SABA prn
- 9 • Regular paediatric moderate/high dose ICS with SABA prn
- 10 • ICS/formoterol maintenance and reliever therapy (MART)
- 11
- 12 Children under 5 years (initial treatment: daily ICS)
- 13 • Step2
- 14 • Moderate dose regular ICS
- 15 • Intermittent montelukast
- 16 • Regular montelukast
- 17 • Regular moderate/high dose ICS/LABA combination
- 18 • Intermittent increases in ICS dose
- 19

20

21 Reference standard stratification:

22

23 In reviews: 1.7

- 24 • Different reference standards
- 25
- 26

## 27 **2.2 Searching for evidence**

### 28 **2.2.1 Clinical and health economics literature searches**

29 The full strategy including population terms, intervention terms, study types applied,  
30 the databases searched, and the years covered can be found in Appendix B of the  
31 evidence review.

32 Systematic literature searches were undertaken to identify published clinical and  
33 health economic evidence relevant to the review questions. These were run  
34 according to the parameters as stipulated within the NICE guideline's manual,  
35 [https://www.nice.org.uk/process/pmg20/chapter/identifying-the-evidence-literature-](https://www.nice.org.uk/process/pmg20/chapter/identifying-the-evidence-literature-searching-and-evidence-submission)  
36 [searching-and-evidence-submission](https://www.nice.org.uk/process/pmg20/chapter/identifying-the-evidence-literature-searching-and-evidence-submission).

37 Databases were searched using relevant medical subject headings, free-text terms  
38 and where appropriate study-type filters. Studies published in languages other than  
39 English were not reviewed, and where possible, searches were restricted to English  
40 language. Searches were updated **between 20<sup>th</sup> to 29<sup>th</sup> December 2023**. Papers  
41 published or added to databases after this date were not considered. Where new  
42 evidence was identified, for example in consultation comments received from  
43 stakeholders, the impact on the guideline was considered, and the action agreed  
44 between the technical team and NICE staff with a quality assurance role.

1 Searches were quality assured using different approaches prior to being run. Medline  
2 search strategies were peer reviewed by a second information specialist using a QA  
3 process based on the PRESS checklist (McGowan, et al., 2016). Key (seed) papers  
4 if provided, were checked if retrieved by the search.

5 Searching for unpublished literature was not undertaken. NICE do not have access to  
6 drug manufacturers' unpublished clinical trial results, so the clinical evidence  
7 considered by the committee for pharmaceutical interventions may be different from  
8 that considered by the MHRA and European Medicines Agency for the purposes of  
9 licensing and safety regulation.

10 Additional studies were added to the evidence base these consisted of references  
11 included in relevant systematic reviews, and those highlighted by committee  
12 members.

## 13 **2.3 Reviewing evidence**

14 The evidence for each review question was reviewed using the following process:

- 15 • Potentially relevant studies were identified from the search results by reviewing  
16 titles and abstracts. The full papers were then obtained.
- 17 • Full papers were evaluated against the pre-specified inclusion and exclusion  
18 criteria set out in the protocol to identify studies that addressed the review  
19 question. The review protocols are included in an appendix to each of the  
20 evidence reports.
- 21 • Relevant studies were critically appraised using the preferred study design  
22 checklist as specified in the NICE guidelines manual.(National Institute for Health  
23 and Care Excellence, 2014), updated 2020. The checklist used is included in the  
24 individual review protocols in each of the evidence reports.
- 25 • Key information was extracted about interventional study methods and results into  
26 EPPI reviewer version 5. Summary evidence tables were produced from data  
27 entered into EPPI Reviewer, including critical appraisal ratings. Key information  
28 about non-interventional study methods and results were manually extracted into  
29 standard Word evidence tables (evidence tables are included in an appendix to  
30 each of the evidence reports).
- 31 • Summaries of the evidence were generated by outcome. Outcome data were  
32 combined, analysed and reported according to study design:
  - 33 ○ Randomised data were meta-analysed where appropriate and reported in  
34 GRADE evidence profiles.
  - 35 ○ Data from non-randomised studies were meta-analysed where appropriate and  
36 reported in GRADE evidence profiles.
  - 37 ○ Diagnostic data were meta-analysed where appropriate or presented as a  
38 range of values in GRADE evidence profiles.
- 39 • A minimum of 10% of the abstracts were reviewed by two reviewers, with any  
40 disagreements resolved by discussion or, if necessary, a third independent  
41 reviewer.
- 42 • All of the evidence reviews were quality assured by a senior systematic reviewer.  
43 This included checking:
  - 44 ○ papers were included or excluded appropriately
  - 45 ○ a sample of the data extractions

- 1           ○ a sample of the risk of bias assessments
- 2           ○ correct methods were used to synthesise data.
- 3           Discrepancies will be identified and resolved through discussion (with a third
- 4           reviewer where necessary).

### 5   **2.3.1   Types of studies and inclusion and exclusion criteria**

6           The inclusion and exclusion of studies was based on the criteria defined in the review  
7           protocols, which can be found in an appendix to each of the evidence reports.  
8           Excluded studies (with the reasons for their exclusion) are listed in an appendix to  
9           each of the evidence reports. The committee was consulted about any uncertainty  
10          regarding inclusion or exclusion.

11          Conference abstracts were not generally considered for inclusion. Literature reviews,  
12          posters, letters, editorials, comment articles, unpublished studies and studies not in  
13          published in English language were excluded.

#### 14   **2.3.1.1   Type of studies**

15          Randomised controlled trials, non-randomised intervention studies, and other  
16          observational studies (including diagnostic or prognostic studies) were included in the  
17          evidence reviews as appropriate.

18          For intervention reviews, randomised controlled trials (RCTs) were included where  
19          identified as because they are considered the most robust type of study design that  
20          can produce an unbiased estimate of the intervention effects. Non-randomised  
21          intervention studies were considered appropriate for inclusion if there was insufficient  
22          randomised evidence for the committee to make a decision. Refer to the review  
23          protocols in each evidence report for full details on the study design of studies that  
24          were appropriate for each review question.

25          For diagnostic review questions, diagnostic RCTs, cross-sectional studies and cohort  
26          studies were included. Case-control studies were not included.

27          Systematic reviews and meta-analyses conducted to the same methodological  
28          standards as the NICE reviews were included within the evidence reviews in  
29          preference to primary studies, where they were available and applicable to the review  
30          questions and updated or added to where appropriate to the guideline review  
31          question. Individual patient data (IPD) meta-analyses were preferentially included if  
32          meeting the protocol and methodological criteria.

## 33   **2.4   Methods of combining evidence**

### 34   **2.4.1   Data synthesis for intervention reviews**

35          Meta-analyses were conducted using Cochrane Review Manager (RevMan5)(Review  
36          Manager (RevMan) [Computer program]. Version 5, 2015) software



## 1 2.4.1.1 Analysis of different types of data

### 2 ***Dichotomous outcomes***

3 Fixed-effects (Mantel–Haenszel) techniques were used to calculate risk ratios  
4 (relative risk, RR) for the binary outcomes. The absolute risk difference was also  
5 calculated using GRADEpro(GRADE Working Group, 2011) software, using the  
6 median event rate in the control arm of the pooled results.

7 For binary variables where there were zero events in either arm or a less than 1%  
8 event rate, Peto odds ratios, rather than risk ratios, were calculated as they are more  
9 appropriate for data with a low number of events. Where there are zero events in  
10 both arms, the risk difference was calculated and reported instead.

### 11 **Continuous outcomes**

12 Continuous outcomes were analysed using an inverse variance method for pooling  
13 weighted mean differences.

14 Where the studies within a single meta-analysis had different scales of measurement  
15 for the same outcomes, standardised mean differences were used (providing all  
16 studies reported either change from baseline or final values rather than a mixture of  
17 both); each different measure in each study was ‘normalised’ to the standard  
18 deviation value pooled between the intervention and comparator groups in that same  
19 study.

20 The means and standard deviations of continuous outcomes are required for meta-  
21 analysis. However, in cases where standard deviations were not reported, the  
22 standard error was calculated if the p values or 95% confidence intervals (95% CI)  
23 were reported, and meta-analysis was undertaken with the mean and standard error  
24 using the generic inverse variance method in RevMan5(Review Manager (RevMan)  
25 [Computer program]. Version 5, 2015).

### 26 ***Generic inverse variance***

27 If a study reported only the summary statistic and 95% CI the generic-inverse  
28 variance method was used to enter data into RevMan5.(Review Manager (RevMan)  
29 [Computer program]. Version 5, 2015) If the control event rate was reported this was  
30 used to generate the absolute risk difference in GRADEpro.(GRADE Working Group,  
31 2011) If multivariate analysis was used to derive the summary statistic but no  
32 adjusted control event rate was reported no absolute risk difference was calculated.

### 33 ***Complex analysis***

34 Where studies had used a crossover design, paired continuous data were extracted  
35 where possible, and forest plots were generated in RevMan5(Review Manager  
36 (RevMan) [Computer program]. Version 5, 2015) with the generic inverse variance  
37 function. When a crossover study had categorical data and the number of subjects  
38 with an event in both interventions was known, the standard error (of the log of the  
39 risk ratio) was calculated using the simplified Mantel–Haenszel method for paired  
40 outcomes. Forest plots were also generated in RevMan5(Review Manager (RevMan)  
41 [Computer program]. Version 5, 2015) with the generic inverse variance function. If  
42 paired continuous or categorical data were not available from the crossover studies,  
43 the separate group data were analysed in the same way as data from parallel

1 groups, on the basis that this approach would overestimate the confidence intervals  
2 and thus artificially reduce study weighting resulting in a conservative effect. Where a  
3 meta-analysis included a mixture of studies using both paired and parallel group  
4 approaches, all data were entered into RevMan5(Review Manager (RevMan)  
5 [Computer program]. Version 5, 2015) using the generic inverse variance function.

## 7 **2.4.2 Data synthesis for diagnostic reviews**

8 One review protocol was produced to reflect the 2 different diagnostic study designs  
9 (diagnostic RCTs and diagnostic accuracy studies).

### 10 **2.4.2.1 Diagnostic RCTs**

11 Diagnostic RCTs (sometimes referred to as test and treat trials) are a randomised  
12 comparison of 2 diagnostic tests, with study outcomes being clinically important  
13 consequences of the diagnosis (patient-related outcome measures similar to those in  
14 intervention trials, such as mortality). Patients are randomised to receive test A or  
15 test B, followed by identical therapeutic interventions based on the results of the test  
16 (so someone with a positive result would receive the same treatment regardless of  
17 whether they were diagnosed by test A or test B). Downstream patient outcomes are  
18 then compared between the 2 groups. As treatment is the same in both arms of the  
19 trial, any differences in patient outcomes will reflect the accuracy of the tests in  
20 correctly establishing who does and does not have the condition. No diagnostic  
21 RCTs were identified from the searches.

### 22 **2.4.2.2 Diagnostic accuracy studies**

23 For diagnostic test accuracy studies, a positive result on the index test was found if  
24 the person had values of the measured quantity above or below a threshold value,  
25 and different thresholds could be used. No ranges for which different thresholds  
26 could be combined were specified by the committee, resulting in reporting of each  
27 individual threshold discretely. The threshold of a diagnostic test is defined as the  
28 value at which the test can best differentiate between those with and without the  
29 target condition. In practice this usually varies across studies. If a test has a high  
30 sensitivity, then very few people with the condition will be missed (few false  
31 negatives). For example, a test with a sensitivity of 97% will only miss 3% of people  
32 with the condition. Conversely, if a test has a high specificity, then few people without  
33 the condition would be incorrectly diagnosed (few false positives).

34 Coupled forest plots of the agreed primary paired outcome measure for decision  
35 making (sensitivity and specificity) with their 95% CIs across studies (at various  
36 thresholds) were produced for each test, using RevMan5.(Review Manager  
37 (RevMan) [Computer program]. Version 5, 2015) In order to do this, 2 by 2 tables  
38 (the number of true positives, false positives, true negatives, and false negatives)  
39 were directly taken from the study if given, or else were derived from raw data or  
40 calculated from the set of test accuracy statistics.

41 Diagnostic meta-analysis was conducted where appropriate, that is, when 3 or more  
42 studies were available per threshold. Test accuracy for the studies was pooled using  
43 the bivariate method for the direct estimation of summary sensitivity and specificity  
44 using a random-effects approach in WinBUGS software.(WinBUGS [Computer

programme] version 1.4, 2015) The advantage of this approach is that it produces summary estimates of sensitivity and specificity that account for the correlation between the 2 statistics. The bivariate method uses logistic regression on the true positives, true negatives, false positives and false negatives reported in the studies. Overall sensitivity and specificity and confidence regions were plotted (using methods outlined by Novielli 2010.(Novielli, et al., 2010)) The pooled median sensitivity and specificity and their 95% CIs were reported in the clinical evidence summary tables. Where two studies reported the same diagnostic threshold, data was presented individually for each study to reflect the uncertainty of the estimates presented and to give the committee a transparent view of the data identified. Where a single study reported a threshold, this was reported individually.

If appropriate, to allow comparison between tests, summary ROC curves were generated for each diagnostic test from the pairs of sensitivity and specificity calculated from the 2 by 2 tables, selecting 1 threshold per study. A ROC plot shows true positive rate (sensitivity) as a function of false positive rate (1 minus specificity). Data were entered into RevMan5(Review Manager (RevMan) [Computer program]. Version 5, 2015) and ROC curves were fitted using the Moses-Littenberg approach. In order to compare diagnostic tests, 2 or more tests were plotted on the same graph. The performance of the different diagnostic tests was then assessed by examining the summary ROC curves visually: the test that had a curve lying closest to the upper left corner (100% sensitivity and 100% specificity) was interpreted as the best test.

## 2.5 Appraising the quality of evidence by outcomes

### 2.5.1 Intervention reviews

The evidence for outcomes from the included RCTs and, where appropriate, non-randomised intervention studies, were evaluated and presented using the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group (<http://www.gradeworkinggroup.org/>). The software (GRADEpro(GRADE Working Group, 2011)) developed by the GRADE working group was used to assess the quality of each outcome, taking into account individual study quality and the meta-analysis results.

Each outcome was first examined for each of the quality elements listed and defined in Table 2.

**Table 2: Description of quality elements in GRADE for intervention studies**

Quality element	Description
Risk of bias	Limitations in the study design and implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis).
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question.

Quality element	Description
Inconsistency	Inconsistency refers to an unexplained heterogeneity of effect estimates between studies in the same meta-analysis.
Imprecision	Results are imprecise when studies include relatively few patients and few events (or highly variable measures) and thus have wide confidence intervals around the estimate of the effect relative to clinically important thresholds. 95% confidence intervals denote the possible range of locations of the true population effect at a 95% probability, and so wide confidence intervals may denote a result that is consistent with conflicting interpretations (for example a result may be consistent with both clinical benefit AND clinical harm) and thus be imprecise.
Publication bias	Publication bias is a systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication of studies. A closely related phenomenon is where some papers fail to report an outcome that is inconclusive, thus leading to an overestimate of the effectiveness of that outcome.
Other issues	Sometimes randomisation may not adequately lead to group equivalence of confounders, and if so this may lead to bias, which should be taken into account. Potential conflicts of interest, often caused by excessive pharmaceutical company involvement in the publication of a study, should also be noted.

1 Details of how the 4 main quality elements (risk of bias, indirectness, inconsistency  
2 and imprecision) were appraised for each outcome are given below. Publication bias  
3 was considered with the committee. If there was reason to suspect it was present, it  
4 was explored with funnel plots. Funnel plots were constructed using RevMan5  
5 software to assess against potential publication bias for outcomes containing more  
6 than 5 studies. This was taken into consideration when assessing the quality of the  
7 evidence.

### 8 2.5.1.1 Risk of bias

9 The main domains of bias for RCTs are listed in Table 3. Each outcome had its risk  
10 of bias assessed within each study first using the appropriate checklist for the study  
11 design (Cochrane RoB 2 for RCTs, or ROBINS-I for non-randomised studies or  
12 ROBIS for systematic reviews). For each study, if there was no risk of bias in any  
13 domain, the risk of bias was given a rating of 'low risk of bias'. An overall judgment of  
14 'some concerns' was made if some concerns were present in at least one domain  
15 and the domain was judged to be at high risk of bias. An overall judgment of 'high  
16 risk of bias' was made if high risk domains in a way that substantially lowers  
17 confidence in the result. An overall rating is of; not serious, serious or very serious, is  
18 applied in GRADEpro across all studies combined in a meta-analysis by taking into  
19 account the weighting of studies according to study precision.

20 **Table 3: Principle domains of bias in randomised controlled trials**

Limitation	Explanation
Selection bias (sequence generation and allocation concealment)	If those enrolling participants are aware of the group to which the next enrolled patient will be allocated, either because of a non-random sequence that is predictable, or because a truly random sequence was not concealed from the researcher, this may translate into systematic selection bias. This may occur if the researcher chooses not to recruit a participant into that specific group because of: <ul style="list-style-type: none"> <li>• knowledge of that participant's likely prognostic characteristics, and</li> </ul>

Limitation	Explanation
	<ul style="list-style-type: none"> <li>• a desire for one group to do better than the other.</li> </ul>
Performance and detection bias (lack of blinding)	<p>Patients, caregivers, those adjudicating or recording outcomes, and data analysts should not be aware of the arm to which the participants are allocated. Knowledge of the group can influence:</p> <ul style="list-style-type: none"> <li>• the experience of the placebo effect</li> <li>• performance in outcome measures</li> <li>• the level of care and attention received, and</li> <li>• the methods of measurement or analysis</li> </ul> <p>all of which can contribute to systematic bias.</p>
Attrition bias	<p>Attrition bias results from an unaccounted for loss of data beyond a certain level (a differential of at least 10% between groups). Loss of data can occur when participants are compulsorily withdrawn from a group by the researchers (for example, when a per-protocol approach is used) or when participants do not attend assessment sessions. If the missing data are likely to be different from the data of those remaining in the groups, and there is a differential rate of such missing data from groups, systematic attrition bias may result.</p>
Selective outcome reporting	<p>Reporting of some outcomes and not others on the basis of the results can also lead to bias, as this may distort the overall impression of efficacy.</p>
Other limitations	<p>For example:</p> <ul style="list-style-type: none"> <li>• Stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules.</li> <li>• Use of unvalidated patient-reported outcome measures.</li> <li>• Lack of washout periods to avoid carry-over effects in crossover trials.</li> <li>• Recruitment bias in cluster-randomised trials.</li> </ul>

1 The assessment of risk of bias differs for non-randomised intervention studies, due to  
 2 the possibility of confounding and the greater risk of selection bias. The assessment  
 3 of risk of bias therefore requires a different checklist (ROBINS-I) and involves  
 4 consideration of more domains and varies by study type. **Table 4** shows the domains  
 5 considered for most types of non-randomised studies.

6 **Table 4 Principle domains of bias in non-randomised studies**

Bias	Explanation
<b>Pre-intervention</b>	
Confounding bias	<p>Baseline confounding occurs when one or more prognostic variables (factors that predict the outcome of interest) also predicts the intervention received at baseline. ROBINS-I can also address time-varying confounding, which occurs when post-baseline prognostic factors affect the intervention received after baseline.</p>
Selection bias	<p>When exclusion of some eligible participants, or the initial follow-up time of some participants, or some outcome events, is related to both intervention and outcome, there will be an association between interventions and outcome even if the effect of interest is truly null. This type of bias is distinct from confounding. A specific example is bias due to the inclusion of prevalent users, rather than new users, of an intervention.</p>
<b>At intervention</b>	
Information bias	<p>Bias introduced by either differential or non-differential misclassification of intervention status. Non-differential misclassification is unrelated to the outcome and will usually bias the estimated effect of intervention towards the</p>

Bias	Explanation
	null. Differential misclassification occurs when misclassification of intervention status is related to the outcome or the risk of the outcome.
<b>Post-intervention</b>	
Confounding bias	Bias that arises when there are systematic differences between experimental intervention and comparator groups in the care provided, which represent a deviation from the intended intervention(s). Assessment of bias in this domain will depend on the effect of interest (either the effect of assignment to intervention or the effect of adhering to intervention).
Selection bias	Bias that arises when later follow-up is missing for individuals initially included and followed (e.g. differential loss to follow-up that is affected by prognostic factors); bias due to exclusion of individuals with missing information about intervention status or other variables such as confounders.
Information bias	Bias introduced by either differential or non-differential errors in measurement of outcome data. Such bias can arise when outcome assessors are aware of intervention status, if different methods are used to assess outcomes in different intervention groups, or if measurement errors are related to intervention status or effects.
Reporting bias	Selective reporting of results from among multiple measurements of the outcome, analyses or subgroups in a way that depends on the findings.

### 1 2.5.1.2 Indirectness

2 Indirectness refers to the extent to which the populations, interventions, comparisons,  
3 and outcome measures are dissimilar to those defined in the inclusion criteria for the  
4 reviews. Indirectness is important when these differences are expected to contribute  
5 to a difference in effect size or may affect the balance of harms and benefits  
6 considered for an intervention. As for the risk of bias, each outcome had its  
7 indirectness assessed within each study first. For each study, if there were no  
8 sources of indirectness, indirectness was given a rating of 'directly applicable'. If  
9 there was indirectness in just 1 source (for example in terms of population),  
10 indirectness was given a rating of 'partially applicable', but if there was indirectness in  
11 2 or more sources (for example, in terms of population and treatment) the  
12 indirectness was given an 'indirectly applicable' rating. An overall rating of; not  
13 serious, serious, or very serious, was applied GRADEpro across all studies by taking  
14 into account the weighting of studies according to study precision.

### 15 2.5.1.3 Inconsistency

16  
17 Inconsistency refers to an unexplained heterogeneity of results for an outcome  
18 across different studies. When estimates of the treatment effect across studies differ  
19 widely, this suggests true differences in the underlying treatment effect, which may  
20 be due to differences in populations, settings or doses. Statistical heterogeneity was  
21 assessed for each meta-analysis estimate by an I-squared ( $I^2$ ) inconsistency statistic.

22 Heterogeneity or inconsistency amongst studies was also visually inspected. Where  
23 statistical heterogeneity as defined above was present or there was clear visual  
24 heterogeneity not captured in the  $I^2$  value predefined subgrouping of studies was  
25 carried out according to the protocol. See the review protocols for the subgrouping  
26 strategy.

1 When heterogeneity was identified for a particular outcome based on  $I^2$  value  
2 ( $I^2 > 50\%$ ) and/or visual inspection of the forest plot (and no plausible explanation  
3 could be found through subgroup analyses), a random effects model was presented  
4 and the quality of evidence for that outcome was downgraded. Inconsistency for that  
5 outcome was given a 'serious' rating if the  $I^2$  was 50–74%, and a 'very serious' rating  
6 if the  $I^2$  was 75% or more.

7 If inconsistency could be explained based on pre-specified subgroup analysis (that is,  
8 each subgroup had an  $I^2 < 50\%$ ) then each of the derived subgroups were presented  
9 separately for that forest plot and GRADE profile (providing at least 2 studies  
10 remained in each subgroup). The committee took this into account and considered  
11 whether to make separate recommendations based on the variation in effect across  
12 subgroups within the same outcome. In such a situation the quality of evidence was  
13 not downgraded.

14 If all predefined strategies of subgrouping were unable to explain statistical  
15 heterogeneity, then a random effects (DerSimonian and Laird) model was employed  
16 to the entire group of studies in the meta-analysis. A random-effects model assumes  
17 a distribution of populations, rather than a single population. This leads to a widening  
18 of the confidence interval around the overall estimate. If, however, the committee  
19 considered the heterogeneity was so large that meta-analysis was inappropriate,  
20 then the results were not pooled and were described narratively.

#### 21 **2.5.1.4 Imprecision**

22 The criteria applied for imprecision were based on the 95% CIs for the pooled  
23 estimate of effect, and the minimal important differences (MID) for the outcome. The  
24 MIDs are the threshold for appreciable benefits and harms, separated by a zone  
25 either side of the line of no effect where there is assumed to be no clinically important  
26 effect. If either end of the 95% CI of the overall estimate of effect crossed 1 of the  
27 MID lines, imprecision was regarded as serious in the GRADEpro rating. This was  
28 because the overall result, as represented by the span of the confidence interval,  
29 was consistent with 2 interpretations as defined by the MID (for example, both no  
30 clinically important effect and clinical benefit were possible interpretations). If both  
31 MID lines were crossed by either or both ends of the 95% CI then imprecision was  
32 regarded as very serious. This was because the overall result was consistent with all  
33 3 interpretations defined by the MID (no clinically important effect, clinical benefit and  
34 clinical harm). This is illustrated in Figure 1.

35 The value / position of the MID lines is ideally determined by values reported in the  
36 literature. 'Anchor-based' methods aim to establish clinically meaningful changes in a  
37 continuous outcome variable by relating or 'anchoring' them to patient-centred  
38 measures of clinical effectiveness that could be regarded as gold standards with a  
39 high level of face validity. For example, a MID for an outcome could be defined by the  
40 minimum amount of change in that outcome necessary to make patients feel their  
41 quality of life had 'significantly improved'. MIDs in the literature may also be based on  
42 expert clinician or consensus opinion concerning the minimum amount of change in a  
43 variable deemed to affect quality of life or health.

44 In the absence of values identified in the literature, the alternative approach to  
45 deciding on MID levels is to use the modified GRADE 'default' values, as follows:

- 46 • For dichotomous outcomes the MIDs were taken to be RRs of 0.8\* and 1.25. For  
47 'positive' outcomes such as 'patient satisfaction', the RR of 0.8 is taken as the line

1 denoting the boundary between no clinically important effect and a clinically  
2 important harm, whilst the RR of 1.25 is taken as the line denoting the boundary  
3 between no clinically important effect and a clinically important benefit. For  
4 'negative' outcomes such as 'bleeding', the opposite occurs, so the RR of 0.8 is  
5 taken as the line denoting the boundary between no clinically important effect and  
6 a clinically important benefit, whilst the RR of 1.25 is taken as the line denoting the  
7 boundary between no clinically important effect and a clinically important harm.  
8 There aren't established default values for ORs and the same values (0.8 and  
9 1.25) are applied here but are acknowledged as arbitrary thresholds agreed by the  
10 committee.

- 11 ○ In cases where there are zero events in one arm of a single study, or some or  
12 all of the studies in one arm of a meta-analysis, the same process is followed  
13 as for dichotomous outcomes. However, if there are no events in either arm in  
14 a meta-analysis (or in a single unpooled study) the sample size is used to  
15 determine imprecision using the following rule of thumb:
  - 16 – No imprecision: sample size  $\geq 350$
  - 17 – Serious imprecision: sample size  $\geq 70$  but  $< 350$
  - 18 – Very serious imprecision: sample size  $< 70$ .
- 19 ○ When there was more than one study in an analysis and zero events occurred  
20 in both groups for some but not all of the studies across both arms, the  
21 optimum information size was used to determine imprecision using the  
22 following guide:
  - 23 – No imprecision:  $> 90\%$  power
  - 24 – Serious imprecision: 80-90% power
  - 25 – Very serious imprecision:  $< 80\%$  power.
- 26 ● For mortality any change was considered to be clinically important, and the  
27 imprecision was assessed on the basis of the whether the confidence intervals  
28 crossed the line of no effect, that is whether the result was consistent with both  
29 benefit and harm.
- 30 ● For continuous outcome variables the MID was taken as half the median baseline  
31 standard deviation (when available) of that variable, across all arms of all studies  
32 in the meta-analysis. If baseline standard deviation was not available for any  
33 studies in the meta-analysis, follow-up standard deviation for the control group  
34 was used for this calculation instead. If baseline SD was reported in some, but not  
35 all studies in a meta-analysis, those that reported baseline values were used for  
36 MID calculation. Where two interventions were compared to one another, for  
37 example in reviews 3.1 and 3.2 where drug classes were compared, the standard  
38 deviation from both arms was used to determine the MID, preferentially using  
39 baseline values, and follow-up values if baseline was not available. Where change  
40 and final values were combined in an analysis, only final value standard deviations  
41 were used. The MID denoting the minimum clinically important benefit was  
42 positive for a 'positive' outcome (for example, a quality of life measure where a  
43 higher score denotes better health), and negative for a 'negative' outcome (for  
44 example, a visual analogue scale [VAS] pain score). Clinically important harms will  
45 be the converse of these. As these vary for each outcome per review, details of  
46 the values used are reported in the footnotes of the relevant GRADE summary  
47 table.
- 48 ● If standardised mean differences have been used, where the GC are able to  
49 specify a priority measure, the results are back-converted to a mean difference on



that scale for the assessment of imprecision and clinical importance. If it is not deemed appropriate to back-convert to a single scale, then the MID was set at the absolute value of +0.5. This follows because standardised mean differences are mean differences normalised to the pooled standard deviation of the 2 groups and are thus effectively expressed in units of 'numbers of standard deviations'. The 0.5 MID value in this context therefore indicates half a standard deviation, the same definition of MID as used for non-standardised mean differences.

\*NB GRADE report the default values as 0.75 and 1.25. These are consensus values. This guideline follows NICE process to use modified values of 0.8 and 1.25 as they are symmetrical on a relative risk scale.

For this guideline, the following MIDs for continuous or dichotomous outcomes were found in the literature and adopted for use:


**Table 5: Published or pre-agreed MIDs**

Outcome measure	MID	Source
EQ-5D	0.03	Consensus pragmatic MID used in some previous NICE guidelines
SF36	Physical component summary: 2 Mental component summary: 3 Physical functioning: 3 Role-physical: 3 Bodily pain: 3 General health: 2 Vitality: 2 Social functioning: 3 Role-emotional: 4 Mental health: 3	User's manual for the SF-36v2 Health Survey, Third Edition(Maruish, 2011)
Asthma quality of life questionnaire (AQLQ and paediatric AQLQ)	0.5	Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47(1): 81-87
Asthma control test (ACT)	3	Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev 2020; 29: 190137
Childhood asthma control test (C-ACT)	2	Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev 2020; 29: 190137
Asthma control questionnaire (ACQ)	0.5	Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev 2020; 29: 190137

Outcome measure	MID	Source
Lung function (PEF)	18.79 L/min	Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? <i>Eur Respir J.</i> 1999 Jul;14(1):23-7.
Lung function (FEV1)	0.23 L	Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? <i>Eur Respir J.</i> 1999 Jul;14(1):23-7.
Reliever/rescue medication use	0.81 puffs/day	Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? <i>Eur Respir J.</i> 1999 Jul;14(1):23-7.

1

**Figure 1:** Illustration of precise and imprecise outcomes based on the 95% CI of dichotomous outcomes in a forest plot (Note that all 3 results would be pooled estimates, and would not, in practice, be placed on the same forest plot)



### 2 2.5.1.5 Overall grading of the quality of clinical evidence

3 Once an outcome had been appraised for the main quality elements, as above, an  
 4 overall quality grade was calculated for that outcome from the ratings from each of  
 5 the main quality elements were summed to give a score that could be anything from  
 6 high to very low. The evidence for each outcome started at High, and the overall  
 7 quality (or confidence in the evidence) remained High if there were no reasons for  
 8 downgrading, or became Moderate, Low or Very Low according to the number of  
 9 independent reasons for downgrading. The significance of these overall ratings is

1 explained in Table 6. The reasons for downgrading in each case are specified in the  
2 footnotes of the GRADE tables.

3 **Table 6: Overall quality of outcome evidence in GRADE**

Level	Description
High	Further research is very unlikely to change our confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low	Any estimate of effect is very uncertain

4 **2.5.2 Diagnostic reviews**

5 **2.5.2.1 Diagnostic RCTs**

6 Appraising the quality of evidence from diagnostic RCTs follows the same process as  
7 section 2.5.1 for intervention reviews.

8 **2.5.2.2 Diagnostic test accuracy**

9 **2.5.2.2.1 Risk of bias**

10 Risk of bias and indirectness of evidence for diagnostic data were evaluated by study  
11 using the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2)  
12 checklists (see appendix H in the NICE guidelines manual 2014(Murray, et al.,  
13 2017)). Risk of bias and applicability in primary diagnostic accuracy studies in  
14 QUADAS-2 consists of 4 domains (see **Table 7**):

- 15 • patient selection
- 16 • index test
- 17 • reference standard
- 18 • flow and timing.

19 **Table 7 Summary of QUADAS-2 with list of signalling, risk of bias and**  
20 **applicability questions.**

Domain	Patient selection	Index test	Reference standard	Flow and timing
Description	Describe methods of patient selection. Describe included patients (prior testing, presentation, intended use of index test and setting)	Describe the index test and how it was conducted and interpreted	Describe the reference standard and how it was conducted and interpreted	Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table (refer to flow diagram). Describe the time interval and any interventions between index test(s) and reference standard

Domain	Patient selection	Index test	Reference standard	Flow and timing
Signalling questions (yes/no/unclear)	Was a consecutive or random sample of patients enrolled?	Were the index test results interpreted without knowledge of the results of the reference standard?	Is the reference standard likely to correctly classify the target condition?	Was there an appropriate interval between index test(s) and reference standard?
	Was a case-control design avoided?	If a threshold was used, was it pre-specified?	Were the reference standard results interpreted without knowledge of the results of the index test?	Did all patients receive a reference standard?
	Did the study avoid inappropriate exclusions?			Did all patients receive the same reference standard?
				Were all patients included in the analysis?
Risk of bias; (high/low/unclear)	Could the selection of patients have introduced bias?	Could the conduct or interpretation of the index test have introduced bias?	Could the reference standard, its conduct or its interpretation have introduced bias?	Could the patient flow have introduced bias?
Concerns regarding applicability (high/low/unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	

#### 12.5.2.2.2 *Inconsistency*

2 Inconsistency refers to an unexplained heterogeneity of results for an outcome  
3 across different studies. Inconsistency was assessed by visual inspection of the  
4 primary outcome measures (sensitivity and specificity) using the point estimates and  
5 95% CIs of the individual studies on the forest plots or the summary value if a  
6 diagnostic meta-analysis had been conducted. The evidence was downgraded by 1  
7 increment if there was no overlap of 95% confidence intervals or by 2 increments if  
8 there was wide variability. Where only a single study reports an outcome,  
9 inconsistency is rated as 'not detected'.

#### 102.5.2.2.3 *Imprecision*

11 The judgement of precision was based on visual inspection of the confidence region  
12 around the summary sensitivity and specificity point from the diagnostic meta-  
13 analysis, if a diagnostic meta-analysis was conducted. Where a diagnostic meta-  
14 analysis was not conducted, imprecision was assessed according to the range of  
15 point estimates or, if only one study contributed to the evidence, the 95% CI around  
16 the single study. The decision thresholds set by the committee were used to

1 determine whether imprecision is not serious, serious or very serious depending on  
2 whether confidence intervals cross zero, one or two thresholds.

#### 32.5.2.2.4 Overall grading

4 Quality rating started at high for prospective and retrospective cross-sectional  
5 studies, and each major limitation (risk of bias, indirectness, inconsistency and  
6 imprecision) brought the rating down by 1 increment to a minimum grade of very low,  
7 as explained for intervention reviews. This was presented in a GRADE evidence  
8 profile.

## 9 2.6 Assessing clinical importance

10 The committee assessed the evidence by outcome in order to determine if there was,  
11 or potentially was, a clinically important benefit, a clinically important harm or no  
12 clinically important difference between interventions. To facilitate this, binary  
13 outcomes were converted into absolute risk differences (ARDs) using  
14 GRADEpro(GRADE Working Group, 2011) software: the median control group risk  
15 across studies was used to calculate the ARD and its 95% CI from the pooled risk  
16 ratio. For continuous outcomes when change and final scores were combined in an  
17 analysis, only final values were used for the calculation of control group risk.

18 The assessment of clinical benefit, harm, or no benefit or harm was based on the  
19 point estimate of absolute effect for intervention studies, which was standardised  
20 across the reviews. The GC agreed a specific threshold to indicate clinical benefit or  
21 harm for severe asthma exacerbations, hospital admissions and emergency  
22 room/A&E visits: 30/1000. For mortality any reduction represented a clinical benefit,  
23 though this finding alone was not regarded sufficient to base recommendations on.  
24 For the remainder of dichotomous outcomes in intervention reviews, the committee  
25 considered that if at least 100 more participants per 1000 (10%) achieved the  
26 outcome of interest in the intervention group compared to the comparison group for a  
27 positive outcome then this intervention was considered beneficial. The same point  
28 estimate but in the opposite direction applied for a negative outcome.

29 For continuous outcomes if the mean difference was greater than the minimally  
30 important difference (MID) then this represented a clinical benefit or harm. For  
31 outcomes such as mortality any reduction or increase was considered to be clinically  
32 important.

33 Established MIDs found in the literature and were agreed to be used for asthma  
34 control (asthma control test, childhood asthma control test and asthma control  
35 questionnaire), lung function (FEV1 in L, PEF in L/min), rescue/reliever medication  
36 use (puffs/day) and quality of life (asthma quality of life questionnaire and paediatric  
37 asthma quality of life questionnaire, EQ-5D and SF-36).

38 The published values used for imprecision and clinical importance are provided in  
39 **Table 5**. For continuous outcomes where the GRADE default MID has been used,  
40 the values for each outcome are provided in the footnotes of the relevant GRADE  
41 tables. Identifying and analysing evidence of cost effectiveness

42 The committee is required to make decisions based on the best available evidence of  
43 both clinical effectiveness and cost effectiveness. Guideline recommendations should  
44 be based on the expected costs of the different options in relation to their expected

1 health benefits (that is, their ‘cost effectiveness’) rather than the total implementation  
2 cost. However, the committee will also need to be increasingly confident in the cost  
3 effectiveness of a recommendation as the cost of implementation increases.  
4 Therefore, the committee may require more robust evidence on the effectiveness and  
5 cost effectiveness of any recommendations that are expected to have a substantial  
6 impact on resources; any uncertainties must be offset by a compelling argument in  
7 favour of the recommendation. The cost impact or savings potential of a  
8 recommendation should not be the sole reason for the committee’s  
9 decision.(National Institute for Health and Care Excellence, 2014)

10 Health economic evidence was sought relating to the key clinical issues being  
11 addressed in the guideline. Health economists:

- 12 • Undertook a systematic review of the published economic literature.
- 13 • Undertook new cost-effectiveness analysis in priority areas.

## 14 **2.6.1 Literature review**

15 The health economists:

- 16 • Identified potentially relevant studies for each review question from the health  
17 economic search results by reviewing titles and abstracts. Full papers were then  
18 obtained.
- 19 • Reviewed full papers against prespecified inclusion and exclusion criteria to  
20 identify relevant studies (see below for details).
- 21 • Critically appraised relevant studies using economic evaluations checklists as  
22 specified in the NICE guidelines manual.(National Institute for Health and Care  
23 Excellence, 2014)
- 24 • Extracted key information about the studies’ methods and results into health  
25 economic evidence tables (which can be found in appendices to the relevant  
26 evidence reports).
- 27 • Generated summaries of the evidence in NICE health economic evidence profile  
28 tables (included in the relevant evidence report for each review question) – see  
29 below for details.

### 30 **2.6.1.1 Inclusion and exclusion criteria**

31 Full economic evaluations (studies comparing costs and health consequences of  
32 alternative courses of action: cost–utility, cost-effectiveness, cost–benefit and cost–  
33 consequences analyses) and comparative costing studies that addressed the review  
34 question in the relevant population were considered potentially includable as health  
35 economic evidence.

36 Studies that only reported cost per hospital (not per patient), or only reported average  
37 cost effectiveness without disaggregated costs and effects were excluded. Literature  
38 reviews, abstracts, posters, letters, editorials, comment articles, unpublished studies  
39 and studies not in English were excluded. Studies published before 2006 and studies  
40 from non-OECD countries or the USA were also excluded, on the basis that the  
41 applicability of such studies to the present UK NHS context is likely to be too low for  
42 them to be helpful for decision-making.

43 Remaining health economic studies were prioritised for inclusion based on their  
44 relative applicability to the development of this guideline and the study limitations. For

1 example, if a high quality, directly applicable UK analysis was available, then other  
2 less relevant studies may not have been included. Where exclusions occurred on this  
3 basis, this is noted in the relevant evidence report.

4 For more details about the assessment of applicability and methodological quality  
5 see **Table 8** below and the economic evaluation checklist (appendix H of the NICE  
6 guidelines manual(National Institute for Health and Care Excellence, 2014)) and the  
7 health economics review protocol, which can be found in each of the evidence  
8 reports.

9 When no relevant health economic studies were found from the economic literature  
10 review, relevant UK NHS unit costs related to the compared interventions were  
11 presented to the committee to inform the possible economic implications of the  
12 recommendations.

### 13 2.6.1.2 NICE health economic evidence profiles

14 NICE health economic evidence profile tables were used to summarise cost and  
15 cost-effectiveness estimates for the included health economic studies in each  
16 evidence review report. The health economic evidence profile shows an assessment  
17 of applicability and methodological quality for each economic study, with footnotes  
18 indicating the reasons for the assessment. These assessments were made by the  
19 health economist using the economic evaluation checklist from the NICE guidelines  
20 manual.(National Institute for Health and Care Excellence, 2014) It also shows the  
21 incremental costs, incremental effects (for example, quality-adjusted life years  
22 [QALYs]) and incremental cost-effectiveness ratio (ICER) for the base case analysis  
23 in the study, as well as information about the assessment of uncertainty in the  
24 analysis. See **Table 8** for more details.

25 When a non-UK study was included in the profile, the results were converted into  
26 pounds sterling using the appropriate purchasing power parity.(Organisation for  
27 Economic Co-operation and Development (OECD))

28 **Table 8: Content of NICE health economic evidence profile**

Item	Description
Study	Surname of first author, date of study publication and country perspective with a reference to full information on the study.
Applicability	An assessment of applicability of the study to this guideline, the current NHS situation and NICE decision-making: <sup>(a)</sup> <ul style="list-style-type: none"> <li>• Directly applicable – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness.</li> <li>• Partially applicable – the study fails to meet 1 or more applicability criteria, and this could change the conclusions about cost effectiveness.</li> <li>• Not applicable – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.</li> </ul>
Limitations	An assessment of methodological quality of the study: <sup>(a)</sup> <ul style="list-style-type: none"> <li>• Minor limitations – the study meets all quality criteria, or fails to meet 1 or more quality criteria, but this is unlikely to change the conclusions about cost effectiveness.</li> </ul>

Item	Description
	<ul style="list-style-type: none"> <li>• Potentially serious limitations – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost effectiveness.</li> <li>• Very serious limitations – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review.</li> </ul>
Other comments	Information about the design of the study and particular issues that should be considered when interpreting it.
Incremental cost	The mean cost associated with one strategy minus the mean cost of a comparator strategy.
Incremental effects	The mean QALYs (or other selected measure of health outcome) associated with one strategy minus the mean QALYs of a comparator strategy.
Cost effectiveness	Incremental cost-effectiveness ratio (ICER): the incremental cost divided by the incremental effects (usually in £ per QALY gained).
Uncertainty	A summary of the extent of uncertainty about the ICER reflecting the results of deterministic or probabilistic sensitivity analyses, or stochastic analyses of trial data, as appropriate.

(a) *Applicability and limitations were assessed using the economic evaluation checklist in appendix H of the NICE guidelines manual (National Institute for Health and Care Excellence, 2014)*

### 2.6.2 Undertaking new health economic analysis

As well as reviewing the published health economic literature for each review question, as described above, new health economic analysis was undertaken by the health economist in selected areas. Priority areas for new analysis were agreed by the committee after formation of the review questions and consideration of the existing health economic evidence.

The committee identified diagnosis of asthma and stepping up treatment for asthma as the highest priority areas for original health economic modelling. The rationale for prioritising these two areas is outlined in the two economic model reports.

The following general principles were adhered to in developing the cost-effectiveness analyses:

- Methods were consistent with the NICE reference case for interventions with health outcomes in NHS settings. (National Institute for Health and Care Excellence, 2014, National Institute for Health and Clinical Excellence, 2013)
- As this guideline updates both the NICE and BTS/SIGN asthma guidelines, the perspective was for both England and Scotland. Where NHS costs were different this was explicitly stated.
- The committee was involved in the design of the model, selection of inputs and interpretation of the results.
- Model inputs were based on the systematic review of the clinical literature supplemented with other published data sources and academic-in-confidence data from a study.
- When published data were not available committee expert opinion was used to populate the model.
- Model inputs and assumptions were reported fully and transparently.
- The results were subject to sensitivity analysis and limitations were discussed.



- 1           • The model was peer-reviewed by another health economist.

2 Full methods and results of the cost-effectiveness analyses are described in the two  
3 respective economic analysis reports.

### 4 **2.6.3 Cost-effectiveness criteria**

5 NICE sets out the principles that committees should consider when judging whether  
6 an intervention offers good value for money. (National Institute for Health and Care  
7 Excellence, 2014, National Institute for Health and Clinical Excellence) In general,  
8 an intervention was considered to be cost effective (given that the estimate was  
9 considered plausible) if either of the following criteria applied:

- 10           • the intervention dominated other relevant strategies (that is, it was both less costly  
11           in terms of resource use and more clinically effective compared with all the other  
12           relevant alternative strategies), or  
13           • the intervention cost less than £20,000 per QALY gained compared with the next  
14           best strategy.

15 If the committee recommended an intervention that was estimated to cost more than  
16 £20,000 per QALY gained, or did not recommend one that was estimated to cost less  
17 than £20,000 per QALY gained, the reasons for this decision are discussed explicitly  
18 in 'The committee's discussion of the evidence' section of the relevant evidence  
19 report, with reference to issues regarding the plausibility of the estimate or to factors  
20 set out in NICE methods manuals. (National Institute for Health and Care Excellence,  
21 2014)

22 When QALYs or life years gained are not used in the analysis, results are difficult to  
23 interpret unless one strategy dominates the others with respect to every relevant  
24 health outcome and cost.

### 25 **2.6.4 In the absence of health economic evidence**

26 When no relevant published health economic studies were found, and a new analysis  
27 was not prioritised, the committee made a qualitative judgement about cost  
28 effectiveness by considering expected differences in resource use between options  
29 and relevant UK NHS unit costs, alongside the results of the review of clinical  
30 effectiveness evidence.

31 The UK NHS costs reported in the guideline are those that were presented to the  
32 committee and were correct at the time recommendations were drafted. They may  
33 have changed subsequently before the time of publication. However, we have no  
34 reason to believe they have changed substantially.

## 35 **2.7 Developing recommendations**

36 Over the course of the guideline development process, the committee was presented  
37 with:

- 38           • Summaries of clinical and health economic evidence and quality (as presented in  
39           evidence reports [A–R]).

- 1 • Evidence tables of the clinical and health economic evidence reviewed from the  
2 literature. All evidence tables can be found in appendices to the relevant evidence  
3 reports.
- 4 • Forest plots (in appendices to the relevant evidence reports).
- 5 • A description of the methods and results of the cost-effectiveness analysis  
6 undertaken for the guideline (in a separate economic analysis report).

7 Decisions on whether a recommendation could be made, and if so in which direction,  
8 were made on the basis of the committee's interpretation of the available evidence,  
9 taking into account the balance of benefits, harms and costs between different  
10 courses of action. This was either done formally in an economic model, or informally.  
11 The net clinical benefit over harm (clinical effectiveness) was considered, focusing on  
12 the magnitude of the effect (or clinical importance), quality of evidence (including the  
13 uncertainty) and amount of evidence available. When this was done informally, the  
14 committee took into account the clinical benefits and harms when one intervention  
15 was compared with another. The assessment of net clinical benefit was moderated  
16 by the importance placed on the outcomes (the committee's values and preferences),  
17 and the confidence the committee had in the evidence (evidence quality). Secondly,  
18 the committee assessed whether the net clinical benefit justified any differences in  
19 costs between the alternative interventions. When the clinical harms were judged by  
20 the committee to outweigh any clinical benefits, they considered making a  
21 recommendation not to offer an intervention. This was dependant on whether the  
22 intervention had any reasonable prospect of providing cost-effective benefits to  
23 people using services and whether stopping the intervention was likely to cause harm  
24 for people already receiving it.

25 When clinical and health economic evidence was of poor quality, conflicting or  
26 absent, the committee decided on whether a recommendation could be made based  
27 on its expert opinion. The considerations for making consensus-based  
28 recommendations include the balance between potential harms and benefits, the  
29 economic costs compared to the economic benefits, current practices,  
30 recommendations made in other relevant guidelines, patient preferences and equality  
31 issues. The consensus recommendations were agreed through discussions in the  
32 committee. The committee also considered whether the uncertainty was sufficient to  
33 justify delaying making a recommendation to await further research, taking into  
34 account the potential harm of failing to make a clear recommendation (see 2.7.1  
35 below).

36 The committee considered the appropriate 'strength' of each recommendation. This  
37 takes into account the quality of the evidence but is conceptually different. Some  
38 recommendations are 'strong' in that the committee believes that the vast majority of  
39 healthcare and other professionals and patients would choose a particular  
40 intervention if they considered the evidence in the same way that the committee has.  
41 This is generally the case if the benefits clearly outweigh the harms for most people  
42 and the intervention is likely to be cost effective. However, there is often a closer  
43 balance between benefits and harms, and some patients would not choose an  
44 intervention whereas others would. This may happen, for example, if some patients  
45 are particularly averse to some side effect and others are not. In these circumstances  
46 the recommendation is generally weaker, although it may be possible to make  
47 stronger recommendations about specific groups of patients.

1 The committee focused on the following factors in agreeing the wording of the  
2 recommendations:

- 3 • The actions health professionals need to take.
- 4 • The information readers need to know.
- 5 • The strength of the recommendation (for example the word 'offer' was used for  
6 strong recommendations and 'consider' for weaker recommendations).
- 7 • The involvement of patients (and their carers if needed) in decisions on treatment  
8 and care.
- 9 • Consistency with NICE's standard advice on recommendations about drugs,  
10 waiting times and ineffective interventions (see section 9.2 in the NICE guidelines  
11 manual(National Institute for Health and Care Excellence)).

12 The main considerations specific to each recommendation are outlined in 'The  
13 committee's discussion of the evidence' section within each evidence report.

### 14 **2.7.1 Research recommendations**

15 When areas were identified for which good evidence was lacking, the committee  
16 considered making recommendations for future research. Decisions about the  
17 inclusion of a research recommendation were based on factors such as:

- 18 • the importance to patients or the population
- 19 • national priorities
- 20 • potential impact on the NHS and future NICE guidance
- 21 • ethical and technical feasibility.

### 22 **2.7.2 Validation process**

23 This guidance is subject to a 6-week public consultation and feedback as part of the  
24 quality assurance and peer review of the document. All comments received from  
25 registered stakeholders are responded to in turn and posted on the NICE website.

### 26 **2.7.3 Updating the guideline**

27 Following publication, and in accordance with the NICE guidelines manual, NICE will  
28 undertake a review of whether the evidence base has progressed significantly to alter  
29 the guideline recommendations and warrant an update.

## 30 **2.8 General terms [methodological terms]**

Term	Definition
Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Algorithm (in guidelines)	A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being

Term	Definition
	administered by someone who is not responsible for recruiting participants.
Annuitisation	The process of spreading out the total cost of purchase of a device over its expected lifespan and converting it into a series of periodic payments. This allows the quantification of the true cost per-test which includes the cost of consumables as well as a part of the initial investment to purchase the device. An annuitisation factor of 3.5% is applied in line with the discounting factor for costs used in NICE economic analyses.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.
Arm (of a clinical study)	Subsection of individuals within a study who receive one particular intervention, for example placebo arm.
Association	Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal.
Base case analysis	In an economic evaluation, this is the main analysis based on the most plausible estimate of each input. In contrast, see Sensitivity analysis.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bayesian analysis	A method of statistics, where a statistic is estimated by combining established information or belief (the 'prior') with new evidence (the 'likelihood') to give a revised estimate (the 'posterior').
Before-and-after study	A study that investigates the effects of an intervention by measuring particular characteristics of a population both before and after taking the intervention, and assessing any change that occurs.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.
Blinding	<p>A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias.</p> <p>A single-blinded study is one in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is one in which neither patients nor the researchers and doctors know which study group the patients are in. A triple blind study is one in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.</p>
Carer (caregiver)	Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.
Case-control study	A study to find out the cause(s) of a disease or condition. This is done by comparing a group of patients who have the disease or condition

Term	Definition
	<p>(cases) with a group of people who do not have it (controls) but who are otherwise as similar as possible (in characteristics thought to be unrelated to the causes of the disease or condition). This means the researcher can look for aspects of their lives that differ to see if they may cause the condition.</p> <p>For example, a group of people with lung cancer might be compared with a group of people the same age that do not have lung cancer. The researcher could compare how long both groups had been exposed to tobacco smoke. Such studies are retrospective because they look back in time from the outcome to the possible causes of a disease or condition.</p>
Case series	Report of a number of cases of a given disease, usually covering the course of the disease and the response to treatment. There is no comparison (control) group of patients.
Clinical efficacy	The extent to which an intervention is active when studied under controlled research conditions.
Clinical effectiveness	<p>How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials.</p> <p>Clinical effectiveness is not the same as efficacy.</p>
Clinician	A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.
Cochrane Review	The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration).
Cohort study	A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study.
Comorbidity	A disease or condition that someone has in addition to the health problem being studied or treated.
Comparability	Similarity of the groups in characteristics likely to affect the study results (such as health status or age).
Concordance	This is a recent term whose meaning has changed. It was initially applied to the consultation process in which doctor and patient agree therapeutic decisions that incorporate their respective views, but now includes patient support in medicine taking as well as prescribing communication. Concordance reflects social values but does not address medicine-taking and may not lead to improved adherence.
Conditional dependence	The statistical relationship of two or more outcomes where the occurrence of one outcome is influenced by the others. In the context of asthma diagnosis, conditional dependence described the likelihood that two or more diagnostic tests give the same result for a particular individual.
Confidence interval (CI)	A range of values for an unknown population parameter with a stated 'confidence' (conventionally 95%) that it contains the true value. The interval is calculated from sample data, and generally straddles the sample estimate. The 'confidence' value means that if the method

Term	Definition
	used to calculate the interval is repeated many times, then that proportion of intervals will actually contain the true value.
Confounding factor	<p>Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.</p> <p>For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor.</p>
Consensus methods	<p>Techniques used to reach agreement on a particular issue.</p> <p>Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.</p>
Control group	<p>A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences.</p> <p>Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.</p>
Cost–consequences analysis (CCA)	<p>Cost–consequences analysis is one of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost–benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.</p>
Cost-effectiveness analysis (CEA)	<p>Cost-effectiveness analysis is one of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).</p>
Cost-effectiveness model	<p>An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.</p>
Cost–utility analysis (CUA)	<p>Cost–utility analysis is one of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.</p>
Decision analysis	<p>An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the clinician through a succession of possible scenarios, actions and outcomes.</p>
Deterministic analysis	<p>In economic evaluation, this is an analysis that uses a point estimate for each input. In contrast, see Probabilistic analysis</p>

Term	Definition
Diagnostic odds ratio	The diagnostic odds ratio is a measure of the effectiveness of a diagnostic test. It is defined as the ratio of the odds of the test being positive if the subject has a disease relative to the odds of the test being positive if the subject does not have the disease.
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Disutility	The loss of quality of life associated with having a disease or condition. See Utility
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals. There are several types of economic evaluation: cost–benefit analysis, cost–consequences analysis, cost-effectiveness analysis, cost-minimisation analysis and cost–utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention.
Effect (as in effect measure, treatment effect, estimate of effect, effect size)	A measure that shows the magnitude of the outcome in one group compared with that in a control group. For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%. The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
Epidemiological study	The study of a disease within a population, defining its incidence and prevalence and examining the roles of external influences (for example, infection, diet) and interventions.
EQ-5D (EuroQol 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients).

Term	Definition
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore cost effective and should be preferred, other things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
Gold standard	A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease.
GRADE, GRADE evidence profile	A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE evidence profile.
Harms	Adverse effects of an intervention.
Hazard Ratio	The hazard or chance of an event occurring in the treatment arm of a study as a ratio of the chance of an event occurring in the control arm over time.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life (HRQoL)	A measure of the effects of an illness to see how it affects someone's day-to-day life.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using one test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.



Term	Definition
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for one treatment compared with another.
Incremental health benefit (IHB)	The value (usually in health terms) of an intervention net of its costs compared with a comparator intervention. The IHB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the IHB is calculated as: QALYs gained – (Incremental cost / £20,000).
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).
Intention-to-treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.
Intervention	In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Kappa statistic	A statistical measure of inter-rater agreement that takes into account the agreement occurring by chance.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Life table model	Markov model with only two states; alive and dead. Annual transition between states taken from a published national life table. Mortality rate can be adjusted using a standardised mortality ratio.
Likelihood ratio	The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity).
Long-term care	Residential care in a home that may include skilled nursing care and help with everyday activities. This includes nursing homes and residential homes.
Logistic regression or Logit model	In statistics, logistic regression is a type of analysis used for predicting the outcome of a binary dependent variable based on one or more predictor variables. It can be used to estimate the log of the odds (known as the 'logit').
Loss to follow-up	A patient, or the proportion of patients, actively participating in a clinical trial at the beginning, but whom the researchers were unable to trace or contact by the point of follow-up in the trial

Term	Definition
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Multivariate model	A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. It is calculated as follows: $TN/(TN+FN)$
Net health benefit (NHB)	The value in health terms of an intervention net of its costs. The NHB can be calculated for a given cost-effectiveness threshold. If the threshold is £20,000 per QALY gained then the NHB for an intervention is calculated as: mean QALYs – (mean cost / £20,000). The most preferable option (that is, the most clinically effective option to have an ICER below the threshold selected) will be the treatment with the highest NHB.
Non-randomised intervention study	A quantitative study investigating the effectiveness of an intervention that does not use randomisation to allocate patients (or units) to treatment groups. Non-randomised studies include observational studies, where allocation to groups occurs through usual treatment decisions or people's preferences. Non-randomised studies can also be experimental, where the investigator has some degree of control over the allocation of treatments.  Non-randomised intervention studies can use a number of different study designs, and include cohort studies, case-control studies, controlled before-and-after studies, interrupted-time-series studies and quasi-randomised controlled trials.
Number needed to treat (NNT)	The average number of patients who need to be treated to get a positive outcome. For example, if the NNT is 4, then 4 patients would have to be treated to ensure 1 of them gets better. The closer the NNT is to 1, the better the treatment.  For example, if you give a stroke prevention drug to 20 people before 1 stroke is prevented, the number needed to treat is 20. See also number needed to harm, absolute risk reduction.
Observational study	Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in one characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening.  There is a greater risk of selection bias than in experimental studies.
Odds ratio	A measure of treatment effectiveness. The odds of an event happening in the treatment group, expressed as a proportion of the odds of it happening in the control group. The 'odds' is the ratio of events to non-events.

Term	Definition
Opportunity cost	The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.
Outcome	The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone's health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins.
P value	The p value is a statistical measure that indicates whether or not an effect is statistically significant. For example, if a study comparing 2 treatments found that one seems more effective than the other, the p value is the probability of obtaining these, or more extreme results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant. If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.
Perioperative	The period from admission through surgery until discharge, encompassing the preoperative and postoperative periods.
Placebo	A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.
Polypharmacy	The use or prescription of multiple medications.
Posterior distribution	In Bayesian statistics this is the probability distribution for a statistic based after combining established information or belief (the prior) with new evidence (the likelihood).
Positive predictive value (PPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. It is calculated as follows: $TP/(TP+FP)$
Postoperative	Pertaining to the period after patients leave the operating theatre, following surgery.
Post-test probability	In diagnostic tests: The proportion of patients with that particular test result who have the target disorder (post-test odds/[1 plus post-test odds]).
Power (statistical)	The ability to demonstrate an association when one exists. Power is related to sample size; the larger the sample size, the greater the

Term	Definition
	power and the lower the risk that a possible association could be missed.
Preoperative	The period before surgery commences.
Pre-test probability	In diagnostic tests: The proportion of people with the target disorder in the population at risk at a specific time point or time interval. Prevalence may depend on how a disorder is diagnosed.
Prevalence	See Pre-test probability.
Prior distribution	In Bayesian statistics this is the probability distribution for a statistic based on previous evidence or belief.
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the one in a study that the power calculation is based on.
Probabilistic analysis	In economic evaluation, this is an analysis that uses a probability distribution for each input. In contrast, see Deterministic analysis.
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group (the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a

Term	Definition
	dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.
RCT	See 'Randomised controlled trial'.
Receiver operated characteristic (ROC) curve	A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.
Reference standard	The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the one that is routinely used in practice.
Reporting bias	See 'Publication bias'.
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.
Review question	In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.
Risk ratio (RR)	<p>The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke).</p> <p>If both groups face the same level of risk, the risk ratio is 1. If the first group had a risk ratio of 2, subjects in that group would be twice as likely to have the event happen. A risk ratio of less than 1 means the outcome is less likely in the first group. The risk ratio is sometimes referred to as relative risk.</p>
Secondary outcome	An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes.
Selection bias	<p>Selection bias occurs if:</p> <ol style="list-style-type: none"> <li>The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or</li> <li>There are differences between groups of participants in a study in terms of how likely they are to get better.</li> </ol>
Sensitivity	<p>How well a test detects the thing it is testing for.</p> <p>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who don't have the disease (that is, give a 'false positive').</p> <p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p>

Term	Definition
	<p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a 'true negative'). But it would probably also miss some people who were 6 months pregnant (that is, give a 'false negative').</p> <p>Breast screening is a 'real-life' example. The number of women who are recalled for a second breast screening test is relatively high because the test is very sensitive. If it were made more specific, people who don't have the disease would be less likely to be called back for a second test but more women who have the disease would be missed.</p>
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p> <p>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).</p>
Significance (statistical)	<p>A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 (<math>p &lt; 0.05</math>).</p>
Specificity	<p>The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.</p> <p>See related term 'Sensitivity'.</p> <p>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.</p>
Stakeholder	<p>An organisation with an interest in a topic that NICE is developing a guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:</p> <ul style="list-style-type: none"> <li>• manufacturers of drugs or equipment</li> <li>• national patient and carer organisations</li> <li>• NHS organisations</li> <li>• organisations representing healthcare professionals.</li> </ul>
State transition model	<p>See Markov model</p>
Stratification	<p>When a different estimate effect is thought to underlie two or more groups based on the PICO characteristics. The groups are therefore kept separate from the outset and are not combined in a meta-</p>

Term	Definition
	analysis, for example; children and adults. Specified a priori in the protocol.
Sub-groups	Planned statistical investigations if heterogeneity is found in the meta-analysis. Specified a priori in the protocol.
Systematic review	A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.
Time horizon	The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.
Transition probability	In a state transition model (Markov model), this is the probability of moving from one health state to another over a specific period of time.
Treatment allocation	Assigning a participant to a particular arm of a trial.
Univariate	Analysis which separately explores each variable in a data set.
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost–utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYES).

1

## 2.9 Acronyms and abbreviations

2

3

Term	Definition
ACQ	Asthma control questionnaire
ACT	Asthma control test
C- ACT	Childhood asthma control test
AQLQ	Asthma quality of life questionnaire
p-AQLQ	Paediatric asthma quality of life questionnaire
FEV1	Forced expiratory volume in one second
PEF	Peak expiratory flow
LABA	Long-acting beta-agonists
SABA	Short-acting beta agonists
LTRA	Leukotriene receptor antagonist
LAMA	Long-acting muscarinic antagonist
BD	'Bis die' (dose given twice a day)
PRN	'Pro re nata' (dose as required)
ICS	Inhaled corticosteroid
CYP	Children and young people
SF-36	Short form 36 (a quality of life measure)
EQ-5D	Quality of life measure developed by EuroQol, with 5 dimensions

4

## 1 2.10 FGlossary

2

Term	Definition
Adherence (to treatment)	The extent to which a patient's action matches the agreed recommendations.
Airway hyper-responsiveness	See 'bronchial hyper-reactivity'.
Asthma	A common long-term incurable condition of unknown cause that affects people of all ages whereby the small tubes in the lungs (bronchi) become inflamed when the person encounters something that irritates their lungs (asthma triggers) causing the airways to become narrower making it difficult to breathe and can induce coughing, wheezing and tightness in the chest. Asthma is usually associated with an expiratory polyphonic wheeze. Severity of symptoms varies from person to person; and even in the same person at different times of the day or year. Worsening of symptoms can occur gradually or suddenly (known as an 'asthma attack' or 'asthma exacerbation').
Asthma attack	A worsening of asthma symptoms requiring the use of systemic corticosteroids to prevent a serious outcome.
Asthma exacerbation	See 'asthma attack'.
Atopic disorders	Allergic conditions including allergic rhinitis (hay fever), atopic dermatitis (eczema), allergic asthma and other specific and non-specific allergic conditions such as food allergies.
Bronchial challenge test	A test to measure airway reactivity after inhalation of a non-specific drug.
Bronchial hyper-responsiveness	A measure of how easily bronchospasm can be induced in the airways.
Bronchodilator	A drug that widens the airways making it easier to breathe.
Bronchodilator response	See 'bronchodilator reversibility'.
Bronchodilator reversibility	A measure of the ability to reverse an obstruction in the airways using drugs that widen the airways (bronchodilators).
Controller medication	See 'Preventer medication'.
Emergency department	Hospital department that assesses and treats patients with serious or life-threatening injuries or illnesses.
Eosinophilia	A higher than normal number of the type of white blood cell eosinophils circulating in the blood.
Exercise	Any physical activity requiring effort or exertion of the body at a greater intensity than that of a normal resting state.
FeNO test	A test that measures the amount of nitric oxide (NO) present upon exhalation, generally expressed in parts per billion.
FEV <sub>1</sub>	The amount of air you can blow out in one second (forced expiratory volume in one second).
Forced vital capacity	The amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
Histamine	An organic chemical compound which is released by cells in the body as part of a local immune response to certain allergic stimuli causing an inflammatory response and the constriction of smooth muscle.



Term	Definition
IgE test	A blood test that measures the amount of IgE antibody circulating in the blood.
Inhaler	A portable device for administering an inhaled drug.
Leukotriene antagonists (LTRA) (also known as leukotriene modifiers and leukotriene receptor antagonists)	A type of oral drug that blocks cysteinyl leukotrienes, used in the treatment of asthma and seasonal allergies.
Long-acting beta-adrenoceptor agonist (LABA)	A long-acting medicine that acts on beta-receptors in the airway to relax airway smooth muscle and relieve symptoms of asthma.
Long-acting muscarinic antagonists (LAMA)	A long-acting medicine that acts on muscarinic receptors in the airway to relax airway smooth muscle and relieve symptoms of asthma.
Maintenance and Reliever Therapy (MART)	A form of combined ICS + LABA treatment in which a single inhaler, containing both ICS and a fast acting LABA, is used for both daily maintenance therapy and the relief of symptoms as required. Low dose/moderate dose MART rulers to dosage of maintenance component.
Mannitol	An osmotic diuretic which leads to constriction of the airways.
Methacholine	A synthetic compound that causes constriction of the airways.
Objective test	A test designed to exclude as far as possible the subjective element on the part of the person taking, the person administering and the person assessing, the test.
Occupational asthma	Work-related asthma attributable to a particular exposure in the workplace and not due to stimuli encountered outside the workplace.
Peak expiratory flow rate	A measure of the maximum speed of expiration, generally expressed in litres per minute.
Peak expiratory flow variability	A measure of how much the maximum speed of expiration varies in a person over time.
Peripheral blood eosinophil count	A blood test that measures the number of the type of white blood cell eosinophils circulating in the blood.
Preventer medication (also known as controller medication)	Inhalers that are used regularly (at least daily) to reduce inflammation in the lungs, improve asthma control and prevent an asthma attack happening, reducing the need to use reliever inhalers.
Questionnaire	A written set of questions on a particular topic designed for the purpose of gathering specific information from a respondent.
Risk stratification	Risk stratification is a process of categorising a population by their relative likelihood of experiencing certain outcomes. In the context of this guideline, risk stratification involves categorising people with asthma by their relative likelihood of experiencing negative clinical outcomes (for example severe exacerbations or hospitalisations). Once the population is stratified, the delivery of care for the population can be targeted with the aim of improving the care of the strata with the highest risk.
Reliever medication	Inhalers that are used to relieve short-term symptoms. The medication delivered is usually a short-acting beta-agonist (SABA) which works by relaxing the muscles surrounding the narrowed airways, allowing them to open wider making breathing easier.

Term	Definition
Rescue medication	Medication used to treat an asthma attack, usually oral corticosteroids and inhaled $\beta$ -2 agonists.
Sensitivity (degree of)	<ul style="list-style-type: none"> <li>• Low: 0-50%</li> <li>• Moderate: 50-75%</li> <li>• High: 75-100%</li> </ul> See also 'Sensitivity' in the list of general terms above.
Skin prick test	A test that measures the allergic response of an individual to certain specific allergens when a very small amount of the specific allergen is introduced into the skin (usually the inner forearm).
Spirometry	A test that measures how a person exhales volumes of air as a function of time.
Tele-healthcare	Information and communication technologies used by patients and healthcare professionals to deliver healthcare, health promotion or to carry out research where the participants are not in the same place. Examples include telephone interviews with a healthcare professional, internet and smartphone-based monitoring support.
Uncontrolled asthma	A term used when asthma is having an impact on a person's lifestyle, or is restricting their normal activities, because of symptoms such as coughing, wheezing, shortness of breath and chest tightness. Uncontrolled asthma can include one or both of: <ul style="list-style-type: none"> <li>• Any asthma exacerbation requiring treatment with oral corticosteroids.</li> <li>• Frequent regular symptoms such as needing a reliever inhaler 3 or more days per week, or having 1 or more nights per week when asthma causes night-time waking. These can be quantified by questionnaires such as the Asthma Control Questionnaire or Asthma Control test.</li> </ul>
Wheeze	A continuous, coarse, whistling sound produced in the airways during breathing (inspiration or expiration) due to a narrowing or obstruction in a part of the respiratory tree. Can be polyphonic (multiple pitches and tones heard over a variable area of the lung) or monophonic (a single pitch and tonal quality heard over an isolated area of the lung).

### 3 References

- 1
- 2 GRADE Working Group. The Grading of Recommendations Assessment,  
3 Development and Evaluation (GRADE) Working Group website. 2011.  
4 Available from: <http://www.gradeworkinggroup.org/> Last accessed:
- 5 Maruish ME (2011) *User's Manual for the SF-36v2 Health Survey*. 3rd edition. Quality  
6 Metric Incorporated.
- 7 McGowan J, Sampson M, Salzwedel DM, et al. (2016) PRESS Peer Review of  
8 Electronic Search Strategies: 2015 Guideline Statement *Journal of Clinical  
9 Epidemiology* 75: 40-46.
- 10 Murray C, Foden P, Lowe L, et al. (2017) Diagnosis of asthma in symptomatic  
11 children based on measures of lung function: an analysis of data from a  
12 population-based birth cohort study *The Lancet Child & adolescent health* 1  
13 (2): 114-123.
- 14 National Institute for Health and Care Excellence. Developing NICE guidelines: the  
15 manual [updated October 2018]. London. National Institute for Health and  
16 Care Excellence, 2014. Available from:  
17 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20o>  
18 [view](http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20o)
- 19 National Institute for Health and Care Excellence. Developing NICE guidelines: the  
20 manual. . London. National Institute for Health and Care Excellence, 2014.  
21 Available from:  
22 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20o>  
23 [view](http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20o)
- 24 National Institute for Health and Clinical Excellence. Guide to the methods of  
25 technology appraisal 2013. London. National Institute for Health and Clinical  
26 Excellence, 2013. Available from: <http://publications.nice.org.uk/pmg9>
- 27 National Institute for Health and Clinical Excellence. Social value judgements:  
28 principles for the development of NICE guidance. London. National Institute  
29 for Health and Clinical Excellence, 2008. Available from:  
30 [https://www.nice.org.uk/media/default/about/what-we-do/research-and-](https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf)  
31 [development/social-value-judgements-principles-for-the-development-of-nice-](https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf)  
32 [guidance.pdf](https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf)
- 33 Novielli N, Cooper NJ, Abrams KR, et al. (2010) How is evidence on test  
34 performance synthesized for economic decision models of diagnostic tests? A  
35 systematic appraisal of Health Technology Assessments in the UK since  
36 1997 *Value in Health* 13 (8): 952-957.
- 37 Organisation for Economic Co-operation and Development (OECD). Purchasing  
38 power parities (PPP). 2012. Available from: <http://www.oecd.org/std/ppp> Last  
39 accessed: 15/03/2024.
- 40 Review Manager (RevMan) [Computer program]. Version 5. Copenhagen. The  
41 Nordic Cochrane Centre, The Cochrane Collaboration, 2015. Available from:  
42 <http://tech.cochrane.org/Revman>

- 1 WinBUGS [Computer programme] version 1.4. Cambridge. MRC Biostatistics Unit
- 2 University of Cambridge, 2015. Available from: <http://www.mrc->
- 3 [bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/](http://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/)

4